Chapter 7 - THE COMPANY THAT BOUGHT SILENCE
Halcyon Pediatric Ventures no longer existed under that name.
Four years earlier, it merged into Solmere Therapeutics.
Most employees moved on.
The neonatal program disappeared.
But the corporate records survived.
The $180,000 payment to Celia was labeled clinical transition consulting.
Some legitimate work supported part of it.
Then investigators found a private memo from Daniel.
Approve Rowan transition payment.
Need complete release on HVP neonatal matter.
A release.
Celia had signed confidentiality language.
Not a confession.
Not bribery on its face.
Still deeply suspicious.
Then the hospital’s role widened.
Risk management had received Hannah’s complaint.
The hospital’s general counsel met with Daniel.
Why?
Because Carter Biomedical had donated $3 million toward a planned NICU expansion.
Emily stared.
“They took his money.”
Hale corrected her.
“The donation preceded Liam’s death by eight months.”
“Did it affect the complaint?”
“We’re investigating.”
The hospital produced board minutes.
One executive warned:
Escalating the Carter matter without confirmed evidence may jeopardize donor relationship and expose institution to litigation.
Another executive replied:
Patient-safety review cannot be influenced by development concerns.
The complaint was still closed.
No smoking gun.
Just institutional pressure.
Then the old risk manager, Peter Sloan, agreed to testify.
He admitted he accepted Celia’s corrected records too easily.
“Why?” Emily asked during a civil deposition.
“Because she was a respected physician.”
“And Daniel?”
“He was threatening suit.”
“And the donation?”
Sloan looked ashamed.
“I knew about it.”
“That isn’t what I asked.”
He looked down.
“Yes. It affected the atmosphere.”
There it was.
Not a hospital-wide murder conspiracy.
Institutional cowardice.
Then Solmere announced a new acquisition.
It planned to buy the remaining assets of Carter Biomedical.
If completed, old Halcyon records would move again under new legal control.
Celia’s confession had been timed to stop that.
Emily learned why.
Daniel was advising the transaction.
Six years later, he was still trying to close a corporate chapter built partly on the same company Liam’s death had protected.
Maya? No—Emily’s civil lawyer, Rachel Morgan, said:
“If the deal closes, records don’t disappear automatically.”
“But access gets harder.”
“Yes.”
Emily looked at the acquisition timeline.
Closing in twenty-one days.
May you like
Another deadline.
Another reason powerful people would say truth could wait until after Friday.
